Keto’s sharpest conversation in Switzerland was not about macros or meal plans. At the Hotel Reine Victoria in St. Moritz, the 6th International Keto Live conference opened as a four-day meeting built around ketogenic metabolic therapies, CME and CPD credit, and a clear push to position keto as a medical tool with real clinical stakes.
The program ran from June 8 through June 12, 2026, with English as the conference language and a call for poster applications open to all scientific fields. Abstracts were due Tuesday, March 31, 2026, at 12 pm CET. The event was open to physicians, medical healthcare professionals, and members of the general public, a mix that gave the conference both a professional and community-facing edge. Parking was available at the venue, and the ticket page said refunds were not offered.
What made the meeting stand out was the disease breadth. The conference framing reached far beyond weight loss and into obesity, insulin resistance, cardiovascular disease, wound healing, cancer, type 1 diabetes, type 2 diabetes, gestational diabetes, chronic kidney disease, ADPKD, food addiction, eating disorders, depression, bipolar disorder, schizophrenia, stroke, and Alzheimer’s disease. That scope made the gathering feel less like a wellness expo and more like a cross-disciplinary clinical forum, where physicians and scientists could compare where ketogenic therapy already has evidence and where better trials are still needed.
The speaker network reflected that direction. Keto Live’s pages highlighted Dr. John Schoonbee, Dr. Zsófia Clemens, Prof. Dr. Stephen Cunnane, Dr. Ian Lake, Dr. David Unwin, Ivor Cummins, and Dr. Markus Bock, names that have become familiar across ketogenic medicine, metabolic health, and advocacy circles. The lineup signaled continuity with earlier Keto Live programming, which has consistently leaned into non-communicable disease and metabolic health rather than simple diet culture.
That clinical turn is exactly what gives the 2026 meeting weight for keto followers watching the field evolve. Recent ADPKD research has described ketosis as a potential strategy, while the KETO-ADPKD trial found the approach feasible and flagged lipid changes as a safety issue to watch. A 2024 type 1 diabetes case report described favorable long-term results, but still called for randomized controlled trials. In cancer, reviews continue to explore ketogenic diets as a possible adjunctive therapy, even as other research raises caution about risks in some settings. The 105th-anniversary framing tied all of that back to a 1921 medical origin point, reminding attendees that keto’s newest debates are still being measured against a century-old therapeutic legacy.
Every story on Keto Diet Magazine is assembled by an automated editorial system that works from verified research, official records, and credible reporting, then clears automated accuracy and moderation checks before it goes live. The standards that system follows are set and overseen by the people who run the publication. Read our full editorial policy.
Know something we missed? Have a correction or additional information?
Submit a Tip
